17,261 trials
Psoriasis
Primary: Number of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75% Improvement at Week 12 — 1; 33; 38; 43 Participants — p=<0.001
Diabetes Mellitus · Hypertension · Metabolic Disease
Primary: Change in BMI Standard Deviation Score — -0.12; -0.06 Standard Deviation Score — p=0.007
Bladder Cancer
Primary: Complete Response Rate at the End of Induction — 46 percentage of participants
Melanoma · Skin Cancer
Primary: Clinical Tumor Regression. — 0; 0; 6; 0 Participants
Immunologic Deficiency Syndrome
Primary: Geometric Least Square Means of Area Under the Curve (AUC) for Plasma Total Immunoglobulin G (IgG) — 7549; 6706 mg*hr/ml
Cardiomyopathy
Primary: Percentage of Participants With Stabilized Transthyretin (TTR Tetramer) at Week 6 — 97.1 Percentage of participants
Leiomyoma
Primary: Shrinkage of Fibroids - Size of Fibroids — -0.27; -0.18; 0.07 logcm3 — p=0.43
Schizophrenia and Disorders With Psychotic Features · Tobacco Use Disorder
Primary: Urinary Cotinine — 755; 1102; 1534; 1408 ng/ml
Cataract
Primary: Percentage of Patients Cured at Day 14, Nepafenac 0.3% vs. Nepafenac Vehicle 0.3% — 64.6; 25.0 Percentage of patients
Influenza · Orthomyxoviruses · Myxovirus Infection
Primary: Summary of the Pre- and Post-Vaccination Geometric Mean Titers (GMTs) for Each of the Influenza Vaccine Antigens. — 25.9; 26.4; 26.6; 184.8 Titers
Transthyretin-associated Amyloidosis With Polyneuropathy
Primary: Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer at Week 6 — 94.7 percentage of participants
Benign Prostatic Hyperplasia
Primary: Change From Baseline in International Prostate Symptom Score (IPSS) at Week 12 — 21.3; 20.2; 21.5; 20.7 Score on a scale
Prostate Cancer
Primary: The Number of Men With Advanced Prostate Cancer Treated With Sunitinib Who Have a Prostate Specific Antigen (PSA) Response — 2 participants
Glioblastoma Multiforme
Primary: Progression-free Survival — 6 Months
Breast Cancer
Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 20 percentage of participants